Trial Review

Registering a new trial?

To achieve prospective registration, we recommend submitting your trial for registration at the same time as ethics submission.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT04757610




Registration number
NCT04757610
Ethics application status
Date submitted
12/02/2021
Date registered
17/02/2021
Date last updated
2/08/2024

Titles & IDs
Public title
OPT-302 With Ranibizumab in Neovascular Age-related Macular Degeneration (nAMD)
Scientific title
A Phase 3, Multicentre, Double-masked, Randomised Study to Evaluate the Efficacy and Safety of Intravitreal OPT-302 in Combination With Ranibizumab, Compared With Ranibizumab Alone, in Participants With nAMD
Secondary ID [1] 0 0
OPT-302-1004
Universal Trial Number (UTN)
Trial acronym
ShORe
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Neovascular Age-related Macular Degeneration 0 0
Condition category
Condition code
Eye 0 0 0 0
Diseases / disorders of the eye

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Other - 2.0 mg OPT-302
Treatment: Other - 0.5 mg ranibizumab
Treatment: Surgery - Sham

Experimental: 0.5 mg ranibizumab with Standard Dosing 2.0 mg OPT-302 - 0.5 mg ranibizumab intravitreal injection administered at 4-weekly intervals.

2.0 mg OPT-302 intravitreal injection administered at 4-weekly intervals.

Experimental: 0.5 mg ranibizumab with Extended Dosing 2.0 mg OPT-302 - 0.5 mg ranibizumab intravitreal injection administered at 4-weekly intervals.

2.0 mg OPT-302 intravitreal injection administered at 4-weekly intervals for three treatments, and then at 8-weekly intervals, with sham intravitreal injection administered at visits when OPT-302 is not.

Sham comparator: 0.5 mg ranibizumab with sham - 0.5 mg ranibizumab intravitreal injection administered at 4-weekly intervals.

Sham intravitreal injection administered at 4-weekly intervals.


Treatment: Other: 2.0 mg OPT-302
intravitreal injection

Treatment: Other: 0.5 mg ranibizumab
intravitreal injection

Treatment: Surgery: Sham
intravitreal injection
Intervention code [1] 0 0
Treatment: Other
Intervention code [2] 0 0
Treatment: Surgery
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Mean change in Early Treatment Diabetic Retinopathy Study (ETDRS) best-corrected visual acuity (BCVA) letters
Timepoint [1] 0 0
Baseline to Week 52
Secondary outcome [1] 0 0
Proportion of participants gaining 15 or more ETDRS BCVA letters
Timepoint [1] 0 0
Baseline to Week 52
Secondary outcome [2] 0 0
Proportion of participants gaining 10 more ETDRS BCVA letters
Timepoint [2] 0 0
Baseline to Week 52
Secondary outcome [3] 0 0
Change in choroidal neovascularisation (CNV) area by fluorescein angiography (FA)
Timepoint [3] 0 0
Baseline to Week 52
Secondary outcome [4] 0 0
Proportion of participants with absence of both sub-retinal fluid and intra-retinal cysts by SD-OCT
Timepoint [4] 0 0
Baseline to Week 52

Eligibility
Key inclusion criteria
* Active subfoveal CNV lesion or juxtafoveal CNV lesion with foveal involvement that is secondary to AMD in the Study Eye.
* An ETDRS BCVA score between 60 and 25 (inclusive) letters in the Study Eye.

Main
Minimum age
50 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
* Any previous treatment for neovascular AMD.
* Clinically significant ocular disorders (other than neovascular AMD), which may interfere with assessment of BCVA, assessment of safety, or fundus imaging.
* Any current (or history of a) social, psychological, or medical condition that precludes enrolment into the study.

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Phase 3
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Active, not recruiting
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
12/03/2021
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
1/07/2026
Actual
Sample size
Target
990
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
NSW,VIC
Recruitment hospital [1] 0 0
ShORe Investigational Site - Hurstville
Recruitment hospital [2] 0 0
ShORe Investigational Site - Melbourne
Recruitment postcode(s) [1] 0 0
2220 - Hurstville
Recruitment postcode(s) [2] 0 0
3050 - Melbourne
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Arizona
Country [2] 0 0
United States of America
State/province [2] 0 0
California
Country [3] 0 0
United States of America
State/province [3] 0 0
Colorado
Country [4] 0 0
United States of America
State/province [4] 0 0
Florida
Country [5] 0 0
United States of America
State/province [5] 0 0
Georgia
Country [6] 0 0
United States of America
State/province [6] 0 0
Illinois
Country [7] 0 0
United States of America
State/province [7] 0 0
Indiana
Country [8] 0 0
United States of America
State/province [8] 0 0
Maryland
Country [9] 0 0
United States of America
State/province [9] 0 0
Massachusetts
Country [10] 0 0
United States of America
State/province [10] 0 0
Minnesota
Country [11] 0 0
United States of America
State/province [11] 0 0
Missouri
Country [12] 0 0
United States of America
State/province [12] 0 0
Nevada
Country [13] 0 0
United States of America
State/province [13] 0 0
New Jersey
Country [14] 0 0
United States of America
State/province [14] 0 0
New York
Country [15] 0 0
United States of America
State/province [15] 0 0
North Carolina
Country [16] 0 0
United States of America
State/province [16] 0 0
North Dakota
Country [17] 0 0
United States of America
State/province [17] 0 0
Oklahoma
Country [18] 0 0
United States of America
State/province [18] 0 0
Oregon
Country [19] 0 0
United States of America
State/province [19] 0 0
Pennsylvania
Country [20] 0 0
United States of America
State/province [20] 0 0
South Carolina
Country [21] 0 0
United States of America
State/province [21] 0 0
Tennessee
Country [22] 0 0
United States of America
State/province [22] 0 0
Texas
Country [23] 0 0
United States of America
State/province [23] 0 0
Utah
Country [24] 0 0
United States of America
State/province [24] 0 0
Virginia
Country [25] 0 0
Argentina
State/province [25] 0 0
Ciudad Autonoma Buenos Aires
Country [26] 0 0
Argentina
State/province [26] 0 0
Santa Fe
Country [27] 0 0
Argentina
State/province [27] 0 0
Sante Fe
Country [28] 0 0
Argentina
State/province [28] 0 0
Buenos Aires
Country [29] 0 0
Argentina
State/province [29] 0 0
Ciudad Autonoma de Buenos Aire
Country [30] 0 0
Argentina
State/province [30] 0 0
Córdoba
Country [31] 0 0
Brazil
State/province [31] 0 0
Cordoba
Country [32] 0 0
Brazil
State/province [32] 0 0
Goias
Country [33] 0 0
Brazil
State/province [33] 0 0
Rio Grande Do Sul
Country [34] 0 0
Brazil
State/province [34] 0 0
Santa Catarina
Country [35] 0 0
Brazil
State/province [35] 0 0
Sao Paulo
Country [36] 0 0
Brazil
State/province [36] 0 0
São Paulo
Country [37] 0 0
Bulgaria
State/province [37] 0 0
Sofia
Country [38] 0 0
Canada
State/province [38] 0 0
Alberta
Country [39] 0 0
Canada
State/province [39] 0 0
Ontario
Country [40] 0 0
Colombia
State/province [40] 0 0
Medellín
Country [41] 0 0
Czechia
State/province [41] 0 0
Pardubice
Country [42] 0 0
Czechia
State/province [42] 0 0
Praha
Country [43] 0 0
Czechia
State/province [43] 0 0
Sokolov
Country [44] 0 0
Denmark
State/province [44] 0 0
Aarhus
Country [45] 0 0
Denmark
State/province [45] 0 0
Glostrup
Country [46] 0 0
Denmark
State/province [46] 0 0
Sønderborg
Country [47] 0 0
France
State/province [47] 0 0
Alpes-Maritimes
Country [48] 0 0
France
State/province [48] 0 0
Bas Rhin
Country [49] 0 0
France
State/province [49] 0 0
Rhone
Country [50] 0 0
France
State/province [50] 0 0
Val De Marr
Country [51] 0 0
Germany
State/province [51] 0 0
Baden Wuerttemberg
Country [52] 0 0
Germany
State/province [52] 0 0
Baden Wuerttermberg
Country [53] 0 0
Germany
State/province [53] 0 0
Niedersachsen
Country [54] 0 0
Germany
State/province [54] 0 0
Nordrhein Westfalen
Country [55] 0 0
Germany
State/province [55] 0 0
Nordrhein
Country [56] 0 0
Germany
State/province [56] 0 0
Hamburg
Country [57] 0 0
Greece
State/province [57] 0 0
Athens
Country [58] 0 0
Greece
State/province [58] 0 0
Ioánnina
Country [59] 0 0
Greece
State/province [59] 0 0
Patra
Country [60] 0 0
Hungary
State/province [60] 0 0
Budapest
Country [61] 0 0
Hungary
State/province [61] 0 0
Miskolc
Country [62] 0 0
Hungary
State/province [62] 0 0
Szombathely
Country [63] 0 0
India
State/province [63] 0 0
Gujarat
Country [64] 0 0
India
State/province [64] 0 0
Karnataka
Country [65] 0 0
India
State/province [65] 0 0
Maharashtra
Country [66] 0 0
India
State/province [66] 0 0
Punjab
Country [67] 0 0
India
State/province [67] 0 0
Tamilnadu
Country [68] 0 0
India
State/province [68] 0 0
Uttar Pradesh
Country [69] 0 0
India
State/province [69] 0 0
West Bengal
Country [70] 0 0
India
State/province [70] 0 0
Mysuru
Country [71] 0 0
Israel
State/province [71] 0 0
Be'er Sheva
Country [72] 0 0
Israel
State/province [72] 0 0
Haifa
Country [73] 0 0
Israel
State/province [73] 0 0
Kfar-Sava
Country [74] 0 0
Israel
State/province [74] 0 0
Petach Tikva
Country [75] 0 0
Israel
State/province [75] 0 0
Rishon LeZion
Country [76] 0 0
Italy
State/province [76] 0 0
Reggio Calabria
Country [77] 0 0
Italy
State/province [77] 0 0
Bologna
Country [78] 0 0
Italy
State/province [78] 0 0
Chieti
Country [79] 0 0
Italy
State/province [79] 0 0
Genova
Country [80] 0 0
Italy
State/province [80] 0 0
Roma
Country [81] 0 0
Italy
State/province [81] 0 0
Siena
Country [82] 0 0
Italy
State/province [82] 0 0
Udine
Country [83] 0 0
Korea, Republic of
State/province [83] 0 0
Gyeonggi-do
Country [84] 0 0
Korea, Republic of
State/province [84] 0 0
Gyeongsangbuk-do
Country [85] 0 0
Korea, Republic of
State/province [85] 0 0
Busan
Country [86] 0 0
Korea, Republic of
State/province [86] 0 0
Gwangju
Country [87] 0 0
Korea, Republic of
State/province [87] 0 0
Seoul
Country [88] 0 0
Latvia
State/province [88] 0 0
Riga
Country [89] 0 0
Malaysia
State/province [89] 0 0
Selangor
Country [90] 0 0
Malaysia
State/province [90] 0 0
Kuala Lumpur
Country [91] 0 0
Poland
State/province [91] 0 0
Gdansk
Country [92] 0 0
Poland
State/province [92] 0 0
Kraków
Country [93] 0 0
Poland
State/province [93] 0 0
Olsztyn
Country [94] 0 0
Poland
State/province [94] 0 0
Szczecin
Country [95] 0 0
Poland
State/province [95] 0 0
Tarnowskie Góry
Country [96] 0 0
Poland
State/province [96] 0 0
Warsaw
Country [97] 0 0
Poland
State/province [97] 0 0
Wroclaw
Country [98] 0 0
Spain
State/province [98] 0 0
Barcelona
Country [99] 0 0
Spain
State/province [99] 0 0
Madrid
Country [100] 0 0
Spain
State/province [100] 0 0
Navarra
Country [101] 0 0
Spain
State/province [101] 0 0
Valencia
Country [102] 0 0
Spain
State/province [102] 0 0
Burgos
Country [103] 0 0
Spain
State/province [103] 0 0
Córdoba
Country [104] 0 0
Thailand
State/province [104] 0 0
Bangkok
Country [105] 0 0
Thailand
State/province [105] 0 0
Chiang Mai
Country [106] 0 0
Thailand
State/province [106] 0 0
Khon Kaen
Country [107] 0 0
Thailand
State/province [107] 0 0
Pathum Thani
Country [108] 0 0
Ukraine
State/province [108] 0 0
Kiev
Country [109] 0 0
United Kingdom
State/province [109] 0 0
Cheshire
Country [110] 0 0
United Kingdom
State/province [110] 0 0
Hampshire
Country [111] 0 0
United Kingdom
State/province [111] 0 0
Leicestershire
Country [112] 0 0
United Kingdom
State/province [112] 0 0
Somerset
Country [113] 0 0
United Kingdom
State/province [113] 0 0
Surrey
Country [114] 0 0
United Kingdom
State/province [114] 0 0
West Midlands
Country [115] 0 0
United Kingdom
State/province [115] 0 0
London

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
Opthea Limited
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
A 2-year, phase 3, multicentre, randomised, parallel-group, sham-controlled, double-masked study. Primary efficacy will be determined at Week 52.
Trial website
https://clinicaltrials.gov/study/NCT04757610
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Opthea Limited
Address 0 0
Country 0 0
Phone 0 0
+61 3 9826 0399
Fax 0 0
Email 0 0
[email protected]
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/study/NCT04757610